138804-35-0

Usage

Molecular structure

Consists of a tetrazole ring, a biphenyl group, and a carboxaldehyde functional group.

Synthesis method

Synthesized by reacting 2-(2-triphenylmethyl-2H-tetrazol-5-yl) benzaldehyde with biphenyl-4-carboxylic acid in the presence of suitable reagents.

Potential applications

Organic synthesis, medicinal chemistry, and material science.

Unique features

Unique structural features and reactivity.

Biological activity

May exhibit biological activity, making it a subject of interest for further research and development.

Upstream product

• 135050-95-2 2'-<2-(triphenylmethyl)-1H-tetrazol-5-yl><1,1'-biphenyl>-4-methanol 
• 1122-91-4 4-bromo-benzaldehyde 
• 143722-25-2 2-(2'-Triphenylmethyl-2'H-tetrazol-5'-yl)-phenylboronic acid 

Downstream Products

• 135050-95-2 2'-<2-(triphenylmethyl)-1H-tetrazol-5-yl><1,1'-biphenyl>-4-methanol 
• 924654-19-3 3-[[(1E)-[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methylene]amino]-1-propanol nitrate 
• 924654-07-9 (E) N-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methylene]-L-valine 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use

The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid

The present invention relates to processes for preparing 1-butyl-2-[2''-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid and to intermediates useful in such processes. The present invention also relates to a process for deprotecting compounds containing a protected 2H-tetrazolyl group, which process comprises reacting a the protected compound with a Lewis acid in the presence of a thiol.

Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid

The present invention relates to a process for preparing 1-butyl-2-[2''-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid and to intermediates useful in such process.

PROCESS FOR PREPARING BIPHENYLTETRAZOLE COMPOUNDS

Method for the preparing biphenyltetrazole compounds which are angiotensin II receptor antagonists or which are useful intermediates to prepare angiotensin II receptor antagonists. An illustrative biphenyl tetrazole compound is 2-n-butyl-4-chloro-1-[(2'-(tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl]-1H-imi dazole-5-methanol, potassium salt.

2-(tetrazol-5-yl)-1,1'-biphenyl derivatives, their preparation and their use as synthetic intermediates

Compounds corresponding to the formula (I) STR1 in which X represents dibromomethyl, formyl, (C1-4)alkyl, or a group CH(OR5)2 or CH(OH)OR5, wherein the or each R5 is hydrogen (C1-3)alkyl or the two R5 's in the case of CH(OR5)2 are linked to provide a 1,3-dioxolane or 1,3-dioxane ring, and Y represents hydrogen, 1,1-dimethylethyl, triphenylmethyl, trimethylstannyl, tributylstannyl, (1,1-dimethylethyl)dimethylsilyl, (1,1-dimethylethyl)diphenylsilyl, 2-cyanoethyl, or a group CH2 OR6 wherein R6 is methyl, phenylmethyl, 1,1-dimethylethyl, 2,2,2-trichloroethyl, benzyloxycarbonyl or 2,2,2-trichloroethyloxycarbonyl, Y being in position 1 or 2 on the tetrazole ring. The compounds of formula (I) are useful as intermediates in the synthesis of compounds possessing therapeutic activity.

Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists

Novel tetrazolylphenylboronic acids, methods for their preparation, and their use in the syntheses of angiotensin II receptor antagonists are disclosed.